Fig. 3

Correlation between irAEs and therapeutic effects. Kaplan–Meier survival curve of PFS (A) and OS (B). PFS and OS following nivolumab treatment in the grade ≥ 2 irAEs group (n = 6) and grade < 2 irAEs group (n = 5). The median PFS was significantly longer in the grade ≥ 2 irAEs group than in the grade < 2 irAEs group (p = 0.0093). OS was significantly longer in the grade ≥ 2 irAEs group than in the grade < 2 irAEs group (p = 0.0108)